From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Portfolio Pulse from Vandana Singh
Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This comes as patents for some blockbuster drugs are nearing expiration. Recent examples include Astellas Pharma acquiring Iveric Bio, Pfizer proposing to acquire Seagen, GSK agreeing to acquire BELLUS Health, and Merck announcing to acquire Prometheus Biosciences. The healthcare sector had a challenging start to 2023 due to regulatory & growth concerns, macroeconomic rotations, and investor preference for large-cap technology stocks.
July 07, 2023 | 5:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astellas Pharma has acquired Iveric Bio for $5.9 billion.
The acquisition of Iveric Bio by Astellas Pharma could potentially strengthen its portfolio and market position, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
GSK has agreed to acquire BELLUS Health for $2 billion.
The acquisition of BELLUS Health by GSK could potentially enhance its product line and market presence, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck has announced to acquire Prometheus Biosciences for $10.8 billion.
The acquisition of Prometheus Biosciences by Merck could potentially boost its product portfolio and market position, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Pfizer has proposed a $43 billion acquisition of Seagen.
The proposed acquisition of Seagen by Pfizer could potentially expand its product offerings and market reach, which could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100